
Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ:DRUG) has closed its overnight offering for gross proceeds of approximately $4 million. The company also announced it will start dosing patients in the trial of proprietary compound of BMB-101 for Dravet Syndrome, a form of child epilepsy.